blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3615522

EP3615522 - C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.06.2022
Database last updated on 03.06.2024
FormerThe patent has been granted
Status updated on  02.07.2021
FormerGrant of patent is intended
Status updated on  28.03.2021
FormerExamination is in progress
Status updated on  13.08.2020
FormerRequest for examination was made
Status updated on  31.01.2020
FormerThe international publication has been made
Status updated on  02.11.2018
Formerunknown
Status updated on  15.05.2018
Most recent event   Tooltip10.05.2024Lapse of the patent in a contracting state
New state(s): HU		published on 12.06.2024 [2024/24]
Applicant(s)For all designated states
Astrazeneca AB
151 85 Södertälje / SE
[2021/31]
Former [2020/10]For all designated states
Astrazeneca AB
151 85 Södertälje / SE
Inventor(s)01 / GRECU, Tudor
1 Francis Crick Avenue Cambridge Biomedical Campus
Cambridge Cambridgeshire CB2 0AA / GB
02 / KETTLE, Jason, Grant
1 Francis Crick Avenue Cambridge Biomedical Campus
Cambridge Cambridgeshire CB2 0AA / GB
03 / PACKER, Martin, John
1 Francis Crick Avenue Cambridge Biomedical Campus
Cambridge Cambridgeshire CB2 0AA / GB
04 / PEARSON, Stuart, Eric
1 Francis Crick Avenue Cambridge Biomedical Campus
Cambridge Cambridgeshire CB2 0AA / GB
05 / SMITH, James, Michael
1 Francis Crick Avenue Cambridge Biomedical Campus
Cambridge Cambridgeshire CB2 0AA / GB
 [2020/10]
Representative(s)Cabinet Becker et Associés
25, rue Louis le Grand
75002 Paris / FR
[2020/10]
Application number, filing date18721348.326.04.2018
[2020/10]
WO2018EP60798
Priority number, dateUS201762490859P27.04.2017         Original published format: US 201762490859 P
[2020/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018197642
Date:01.11.2018
Language:EN
[2018/44]
Type: A1 Application with search report 
No.:EP3615522
Date:04.03.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 01.11.2018 takes the place of the publication of the European patent application.
[2020/10]
Type: B1 Patent specification 
No.:EP3615522
Date:04.08.2021
Language:EN
[2021/31]
Search report(s)International search report - published on:EP01.11.2018
ClassificationIPC:C07D403/12, C07D405/14, A61K31/517, A61P35/00
[2020/10]
CPC:
C07D403/12 (EP,KR,RU,US); A61K31/517 (KR,RU); A61K31/5377 (RU);
A61P35/00 (EP,KR,RU,US); C07D405/14 (EP,RU,US); A61K2121/00 (KR,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/10]
Extension statesBA27.11.2019
ME27.11.2019
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:C5-QUINAZOLIN VERBINDUNGEN UND IHRE VERWENDUNG ZUR KREBSBEHANDLUNG[2021/15]
English:C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER[2020/10]
French:COMPOSÉS DE C5-QUINAZOLEINE ET LEUR UTILISATION POUR LA TRAITENET DE LA CANCER.[2021/15]
Former [2020/10]C5-ANILINOCHINAZOLINVERBINDUNGEN UND IHRE VERWENDUNG ZUR BEHANDLUNG VON KREBS
Former [2020/10]COMPOSÉS DE C5-ANILINOQUINAZOLINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
Entry into regional phase27.11.2019National basic fee paid 
27.11.2019Designation fee(s) paid 
27.11.2019Examination fee paid 
Examination procedure27.11.2019Examination requested  [2020/10]
27.11.2019Date on which the examining division has become responsible
08.06.2020Amendment by applicant (claims and/or description)
12.08.2020Despatch of a communication from the examining division (Time limit: M04)
10.12.2020Reply to a communication from the examining division
29.03.2021Communication of intention to grant the patent
28.06.2021Fee for grant paid
28.06.2021Fee for publishing/printing paid
28.06.2021Receipt of the translation of the claim(s)
Opposition(s)06.05.2022No opposition filed within time limit [2022/28]
Fees paidRenewal fee
31.03.2020Renewal fee patent year 03
19.04.2021Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.04.2018
AL04.08.2021
AT04.08.2021
CY04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
MC04.08.2021
MK04.08.2021
NL04.08.2021
PL04.08.2021
RO04.08.2021
RS04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
IE26.04.2022
LU26.04.2022
[2024/24]
Former [2024/23]AL04.08.2021
AT04.08.2021
CY04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
MC04.08.2021
MK04.08.2021
NL04.08.2021
PL04.08.2021
RO04.08.2021
RS04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
IE26.04.2022
LU26.04.2022
Former [2024/20]AL04.08.2021
AT04.08.2021
CY04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
MC04.08.2021
NL04.08.2021
PL04.08.2021
RO04.08.2021
RS04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
IE26.04.2022
LU26.04.2022
Former [2023/20]AL04.08.2021
AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
MC04.08.2021
NL04.08.2021
PL04.08.2021
RO04.08.2021
RS04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
IE26.04.2022
LU26.04.2022
Former [2023/08]AL04.08.2021
AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
MC04.08.2021
NL04.08.2021
PL04.08.2021
RO04.08.2021
RS04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
LU26.04.2022
Former [2023/06]AL04.08.2021
AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
MC04.08.2021
NL04.08.2021
PL04.08.2021
RO04.08.2021
RS04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/36]AL04.08.2021
AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
NL04.08.2021
PL04.08.2021
RO04.08.2021
RS04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/29]AL04.08.2021
AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
NL04.08.2021
PL04.08.2021
RO04.08.2021
RS04.08.2021
SE04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/25]AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
NL04.08.2021
PL04.08.2021
RO04.08.2021
RS04.08.2021
SE04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/24]AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
NL04.08.2021
PL04.08.2021
RO04.08.2021
RS04.08.2021
SE04.08.2021
SK04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/21]AT04.08.2021
DK04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
NL04.08.2021
PL04.08.2021
RS04.08.2021
SE04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/16]AT04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
NL04.08.2021
PL04.08.2021
RS04.08.2021
SE04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/10]AT04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
PL04.08.2021
RS04.08.2021
SE04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/09]AT04.08.2021
FI04.08.2021
LT04.08.2021
RS04.08.2021
SE04.08.2021
BG04.11.2021
NO04.11.2021
PT06.12.2021
Former [2022/08]AT04.08.2021
FI04.08.2021
LT04.08.2021
SE04.08.2021
BG04.11.2021
NO04.11.2021
Former [2022/07]AT04.08.2021
LT04.08.2021
NO04.11.2021
Cited inInternational search[A]US2006178382  (MORTLOCK ANDREW A [GB], et al) [A] 1-20 * paragraph [[0008]]; example -; claim - *;
 [A]US7709479  (MORTLOCK ANDREW AUSTEN [GB], et al) [A] 1-20 * claim -; table 4 *;
 [A]  - G-W RAO ET. AL., "Synthesis, Antitumor Evaluation, and Docking Study of Novel 4-Anilinoquinazoline Derivatives as Potential Epidermal Growth Factor (EGFR) Inhibitors.", CHEMMEDCHEM, (20130601), vol. 8, no. 6, doi:10.1002/cmdc.201300120, pages 928 - 933, XP002781576 [A] 1-20 * Table 1, compounds 4a to 4g *

DOI:   http://dx.doi.org/10.1002/cmdc.201300120
by applicant   - M. A. LEMMON; K. M. FERGUSON, Cell, (20070000), vol. 130, page 213
    - K. VERSTRAETE; S. N. SAVVIDES, Nat. Rev. Cancer, (20120000), vol. 12, page 753
    - J. LENNARTSSON; L. RONNSTRAND, Physiol Rev., (20120000), vol. 92, page 1619
    - J. P. DINITTO et al., J. Biochem., (20100000), vol. 147, page 601
    - C. BAHLAWANE et al., Cell Commun. Signal., (20150000), vol. 13, page 21
    - C. M. BARNETT; C. L. CORLESS; M. C. HEINRICH, Hematol. Oncol. Clin. North Am., (20130000), vol. 27, page 871
    - S. HIROTA et al., Science, (19980000), vol. 279, page 577
    - J. A. FLETCHER, Cancer Res., (20160000), vol. 76, page 6140
    - G. D. DEMETRI et al., N. Engl. J. Med., (20020000), vol. 347, page 472
    - J. VERWEIJ et al., Lancet, (20040000), vol. 364, page 1127
    - C. D. BLANKE et al., J. Clin. Oncol., (20080000), vol. 26, page 626
    - METAGIST, J. Clin. Oncol., (20100000), vol. 28, page 1247
    - C. R. ANTONESCU et al., Clin. Cancer Res., (20050000), vol. 11, page 4182
    - M. C. HEINRICH et al., J. Clin. Oncol., (20060000), vol. 24, page 4764
    - G. D. DEMETRI et al., Lancet, (20060000), vol. 368, page 1329
    - M. C. HEINRICH et al., J. Clin. Oncol., (20080000), vol. 26, page 5352
    - G. D. DEMETRI et al., Lancet, (20130000), vol. 381, page 295
    - STERN et al., Critical Reviews in Oncology/Haematology, (20050000), vol. 54, pages 1 - 29
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.